Repository logo
 

Network-based prioritisation and validation of regulators of vascular smooth muscle cell proliferation in disease

Published version
Peer-reviewed

Repository DOI


Change log

Abstract

Aberrant vascular smooth muscle cell (VSMC) homeostasis and proliferation characterise vascular diseases causing heart attack and stroke. Here, we elucidate molecular determinants governing VSMC proliferation by reconstructing gene regulatory networks from single-cell transcriptomics and epigenetic profiling. We detect wide-spread activation of enhancers at disease-relevant loci in proliferation-predisposed VSMCs. We compared transcriptional network rewiring between injury responsive and non-responsive VSMCs, which suggested shared transcription factors but differing target loci between VSMC states. Through in silico perturbation analysis, we identified and prioritised previously unrecognised regulators of proliferation, including RUNX1 and TIMP1. Moreover, we demonstrated that the pioneer transcription factor RUNX1 increased VSMC responsiveness and show that TIMP1 feeds back to promote VSMC proliferation through CD74-mediated STAT3 signalling. Both RUNX1 and the TIMP1-CD74 axis were expressed in human VSMCs, showing low levels in normal arteries and increased expression in disease, suggesting clinical relevance and potential as vascular disease targets.

Description

Funder: Deutsche Forschungsgemeinschaft, Bonn, Germany: KR2047/8-1, KR2047/14-1, and KR2047/15-1


Funder: Chan Zuckerberg Initiative 2018-190766/RG98793

Journal Title

Nature Cardiovascular Research

Conference Name

Journal ISSN

2731-0590
2731-0590

Volume Title

3

Publisher

Springer

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
British Heart Foundation (CH/2000003/12800)
British Heart Foundation (FS/19/54/34889B)
British Heart Foundation (PG/19/6/34153)
British Heart Foundation (None)
British Heart Foundation (CH/2000003/12800)
Cambridge University Hospitals NHS Foundation Trust (CUH) (BRC4 Y1)
British Heart Foundation (RG/20/2/34763)
British Heart Foundation (RE/18/1/34212)
Department of Health (via National Institute for Health Research (NIHR)) (202375)
British Heart Foundation (CH/2000003)
British Heart Foundation (None)
British Heart Foundation (FS/15/38/31516)
British Heart Foundation (PG/16/11/32021)
This work was supported by the British Heart Foundation (PG/19/6/34153, FS/15/62/32032, FS/15/38/31516, RM/13/3/30159, RE/13/ 6/30180, RE/18/1/34212, CH/2000003/12800, PG/23/11350, M.R.B., H.F.J., M. S.; RG/16/13/32609, RG/19/9/34655, PG/16/9/31995, PG/18/73/34059, SP/19/2/344612, S.Y., T.R.W.; AA/18/3/34220, C.U.S.), the Cambridge NIHR Biomedical Research Centre, the Deutsche Forschungsgemeinschaft, Bonn, Germany (KR2047/8-2, KR2047/14-1, KR2047/15-1, KR2047/16-1, A.K.), the Medical Research Council of the UK (MC-A652-5QA20, M.S., core-funded investigator), Singapore's National Medical Research Council (CIRG22jul‐0002, S.Y.), National University of Singapore and National University Health System (NUHSRO/2022/004/Startup/01, S.Y), the National Institute for Health Research Leicester Biomedical Research Centre, and the Chan Zuckerberg Initiative (2018-190766/RG98793, the Collaborative Bioresource for Translational Medicine, K.T.M.).

Relationships

Is derived from: